Sort
48,018 grants matching “immunotherapy”
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
$995,160Matthew F. Mackey · Immunext, Inc. · R42 · FY2014 · AI
Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies
$995,112Raffit Hassan · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry
$994,901Christine B. Ambrosone · Roswell Park Cancer Institute Corp · R01 · FY2020 · CA
Cancer and Leukemia Group B-Leukemia Correlative Science
$994,868Michael A Caligiuri · Ohio State University · U10 · FY2007 · CA
Leadership, Planning and Evaluation
$994,847Caryn Lerman · University Of Southern California · P30 · FY2023 · CA
A Single-cell Platform for Analyzing the Peripheral Immune Response in Alzheimerâs and Alzheimerâs Related Diseases
$994,372Timothy S McConnell · Isoplexis, Inc. · R44 · FY2021 · AG
Role of HIV Envelope Proteins In Viral Replication and HIV Pathogenesis
$994,320Claudia Cicala · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Reprogramming the Tumor-Immune Interface in Oral Cancer
$994,309John B Sunwoo · Stanford University · R35 · FY2023 · DE
A novel immuno-oncolytic viral therapy for the treatment of non-small cell lung carcinoma
$994,294Stephen H Thorne · Western Oncolytics, Ltd · R44 · FY2020 · CA
STING Activators as Therapy for Cancer
$993,879Glen N Barber · Stinginn, Llc · R42 · FY2023 · CA
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
$993,747Roger L Shapiro · Harvard School Of Public Health · U01 · FY2023 · AI
NOVEL TRANSFUSION BASED IMMUNE MODULATION
$993,693Stanford University · P01 · FY2001 · HL
PEDIATRIC AIDS CLINICAL TRIAL UNIT
$993,528Univ Of Massachusetts Med Sch Worcester · U01 · FY2003 · AI
TrialNet: Diabetes Type 1 Prevention Trial
$993,520Peter A Gottlieb · University Of Colorado Denver · U01 · FY2007 · DK
Reducing Cancer Health Disparities in Detroit
$993,382Ann G Schwartz · Wayne State University · P20 · FY2021 · CA
Regulation of Lymphocyte Proliferation and Replicative Capacity
$993,254Richard J. Hodes · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
STING Activators as Therapy for Cancer
$993,220Glen N Barber · Stinginn, Llc · R42 · FY2022 · CA
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry
$993,003Christine B. Ambrosone · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA
Developing novel LOX inhibitors to target chemotherapy resistant TNBC
$992,932Ozgur Sahin · Loxigen, Inc. · R42 · FY2024 · CA
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer
$992,724Dashtimoghadam Erfan · Symphony Biosciences, Inc. · R44 · FY2024 · CA
A human cytomegalovirus-based immunotherapy for HIV-1
$992,696Eric Bruening · Tomegavax, Inc. · R44 · FY2014 · AI
Molecular, Cellular, and Tissue Characterization Unit
$992,570William E Gillanders · Washington University · U2C · FY2020 · CA
Immunomodulatory AVM0703 to bridge Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients to CAR-T cell immunotherapy
$992,425Theresa Deisher · Avm Biotechnology, Llc · R44 · FY2025 · CA
Human natural killer cells: Advancing biology and clinical applications
$992,214Michael A Caligiuri · Beckman Research Institute/City Of Hope · R35 · FY2018 · CA
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
$992,188Matthew L Meyerson · Dana-Farber Cancer Inst · R35 · FY2024 · CA